| Stereochemistry | RACEMIC |
| Molecular Formula | C11H12N2O2 |
| Molecular Weight | 204.2252 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C(=O)NC(C1=O)C2=CC=CC=C2
InChI
InChIKey=SZQIFWWUIBRPBZ-UHFFFAOYSA-N
InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin inhibits nerve impulses in the motor cortex by lowering sodium ion influx, limiting tetanic stimulation. Ethotoin is used for the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures. Ethotoin is marketed as Peganone by Ovation.
CNS Activity
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Sourcing
PubMed
Patents
Sample Use Guides
PEGANONE (ethotoin tablets, USP) is administered orally in 4 to 6 divided doses
daily. The drug should be taken after food, and doses should be spaced as
evenly as practicable. Initial dosage should be conservative. For adults, the initial
daily dose should be 1 g or less, with subsequent gradual dosage increases over
a period of several days. The optimum dosage must be determined on the basis
of individual response. The usual adult maintenance dose is 2 to 3 g daily. Less
than 2 g daily has been found ineffective in most adults.
Route of Administration:
Oral
ACTIVE MOIETY
